2022, May

Attgeno reports on the completed Phase I study of the drug candidate, Supernitro

The last of 38 study participants were treated with Supernitro on 18 May, and the substance has shown good safety and tolerability. No unexpected side effects have been reported. At a higher dose and longer treatment, the expected side effects have been noted in line with the substance mechanism of action – vasodilation through the release of nitric oxide (NO). Read more